Urovant Sciences Ltd. believes it has the data in hand to support a 2020 FDA filing for its overactive bladder drug vibegron, with the EMPOWUR trial hitting on all endpoints versus placebo, but underperforming against the generic anticholinergic tolterodine leaves it in a tricky commercial situation – and investors are expressing doubts.
On a March 19 investor call to outline the data, Urovant said vibegron should offer a quicker onset of action...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
